Company Monitoring Page for Eli-Lilly

latest headlines for company on cafepharma

Lilly, Takeda Face Class-Action Racketeering Lawsuit Over Diabetes Drug
BioSpace
Thu, 06/8/23 - 09:56 am
Tags:
Eli Lilly, Takeda, legal, Actos, bladder cancer, diabetes, racketeering
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Tags:
Alzheimer's disease, FDA, insurance, Leqembia, Biogen, Eisai, Eli Lilly, donanemab
Why Lilly is trying new strokes to persevere against pain
Fierce Biotech
Mon, 06/5/23 - 10:02 am
Tags:
Eli Lilly, chronic pain, CROs
Novo seeks a cardiovascular boost
EP Vantage
Thu, 06/1/23 - 11:23 am
Tags:
Novo Nordisk, Wegovy, Eli Lilly, Mounjaro
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Wed, 05/31/23 - 07:02 pm
Tags:
Alzheimer's disease, patients, clinical trials, Biogen, Eisai, Eli Lilly
Sequoia China-Backed AI Startup Xtalpi To Partner With Pharma Giant Eli Lilly In $250 Million Novel Drug Deal
Forbes
Wed, 05/31/23 - 11:12 am
Tags:
Eli Lilly, drug discovery, China, artificial intelligence, XtalPi
Global obesity drugs sales could top $44bn in 2030, says Bloomberg Intelligence
Biopharma Reporter
Wed, 05/31/23 - 11:08 am
Tags:
obesity, weight loss, Novo Nordisk, Eli Lilly, Pfizer, Amgen
Eli Lilly settles insulin suit for $13.5 million, agrees to keep price cap
Washington Post, DC
Tue, 05/30/23 - 09:25 pm
Tags:
Eli Lilly, insulin, legal, drug pricing
Noom to offer prescriptions for weight-loss drugs
Yahoo Finance
Fri, 05/26/23 - 10:05 am
Tags:
Noom, weightloss, Novo Nordisk, Eli Lilly, Wegovy, Ozempic, Mounjaro
Lilly steps up its oral obesity push
EP Vantage
Thu, 05/25/23 - 08:45 pm
Tags:
Eli Lilly, obesity, GLP-1 agonist, orforglipron
Here come the PD-1 agonists
EP Vantage
Tue, 05/23/23 - 09:49 am
Tags:
PD-1 agonists, autoimmune disease, Eli Lilly, rheumatoid arthritis, peresolimab
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Drugs.com
Thu, 05/18/23 - 08:32 pm
Tags:
Eli Lilly, peresolimab, rheumatoid arthritis, clinical trials
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
Fierce Biotech
Tue, 05/16/23 - 12:01 pm
Tags:
Scribe Therapeutics, Eli Lilly, CRISPR, Prevail Therapeutics, gene therapy, biobucks, Jennifer Doudna
New Eli Lilly-backed neurological disease biotech Nido unveils with $109M
Fierce Biotech
Mon, 05/15/23 - 10:12 am
Tags:
Nido Bioscineces, Eli Lilly, neurological disorders, Kennedy's disease, precision medicine
Next-gen Lilly obesity drug slashes weight in Innovent study—but is it enough to rival Mounjaro?
Fierce Biotech
Fri, 05/12/23 - 11:41 am
Tags:
Innovent, Eli Lilly, obesity, mazdutide, clinical trials
2023’s biggest launches: the story so far
EP Vantage
Fri, 05/12/23 - 10:19 am
Tags:
drug launches, AbbVie, Almirall, Apellis Pharmaceuticals, Astellas, AstraZeneca, Biogen, CRISPR Therapeutics, Daiichi Sankyo, Eli Lilly, Genmab, GSK, Iveric Bio, Pfizer, Roche, SAGE Therapeutics, Sanofi, Sarepta Therapeutics, Shionogi, Swedish Orphan Biovitrum, Vertex Pharmaceuticals
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
BioPharma Dive
Thu, 05/11/23 - 11:14 am
Tags:
Eli Lilly, donanemab, Alzheimer's disease, physicians
What you need to know about pharma, PBM execs testifying on insulin prices
Medical Marketing and Media
Wed, 05/10/23 - 11:15 pm
Tags:
PBMs, insulin, diabetes, drug pricing, Sanofi, Novo Nordisk, Eli Lilly
Eli Lilly damages tripled to $184M in Medicaid rebate fraud case
Fierce Pharma
Wed, 05/10/23 - 11:07 pm
Tags:
Eli Lilly, legal, fraud, Medicare
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Wed, 05/10/23 - 10:18 am
Tags:
Gilead Sciences, GSK, momelotinib, Roche, Eli Lilly, lebrikizumab, Merck, Zejula, Amgen, Galenica, Veltassa, Cubicin

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.